“The acquisition of Atrium is an excellent strategic fit with our long-term business goals as Atrium’s robust product line complements MAQUET Cardiovascular’s existing therapy options and provides additional solutions for the customers that we serve,” said Christian Keller, president and chief executive officer of MAQUET Cardiovascular. “Like MAQUET, innovation is at the core of Atrium’s business and we believe that this acquisition will allow us to leverage the scientific and technological advances across both organisations so that we may continue to deliver ground-breaking solutions to customers and patients worldwide.”
“MAQUET Cardiovascular’s heritage and global leadership in the interventional cardiology, vascular surgery and cardiopulmonary spaces provides us the resources necessary to continue to grow our business and better serve our customers around the world,” said Trevor Carlton, president, Atrium Medical. “We believe the similarities in our cultures and business focus, coupled with our ability to continue to work independently will allow our sales team, researchers and scientists to further unlock the value of the core technologies that have driven our success to date.”
The transaction is expected to close in the fourth quarter of 2011, subject to U.S. Federal Trade Commission (FTC) approval.